[A case of auditory agnosia].

G. Assal,P. Despland

Abstract:

What problem does this paper attempt to address?

Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App

Pau Herrero,Magí Andorrà,Nils Babion,Hendericus Bos,Matthias Koehler,Yannick Klopfenstein,Eemeli Leppäaho,Patrick Lustenberger,Ajandek Peak,Christian Ringemann,Timor Glatzer

DOI: https://doi.org/10.1177/19322968241267818

Abstract:Background: Despite abundant evidence demonstrating the benefits of continuous glucose monitoring (CGM) in diabetes management, a significant proportion of people using this technology still struggle to achieve glycemic targets. To address this challenge, we propose the Accu-Chek® SmartGuide Predict app, an innovative CGM digital companion that incorporates a suite of advanced glucose predictive functionalities aiming to inform users earlier about acute glycemic situations. Methods: The app's functionalities, powered by three machine learning models, include a two-hour glucose forecast, a 30-minute low glucose detection, and a nighttime low glucose prediction for bedtime interventions. Evaluation of the models' performance included three data sets, comprising subjects with T1D on MDI (n = 21), subjects with type 2 diabetes (T2D) on MDI (n = 59), and subjects with T1D on insulin pump therapy (n = 226). Results: On an aggregated data set, the two-hour glucose prediction model, at a forecasting horizon of 30, 45, 60, and 120 minutes, achieved a percentage of data points in zones A and B of Consensus Error Grid of: 99.8%, 99.3%, 98.7%, and 96.3%, respectively. The 30-minute low glucose prediction model achieved an accuracy, sensitivity, specificity, mean lead time, and area under the receiver operating characteristic curve (ROC AUC) of: 98.9%, 95.2%, 98.9%, 16.2 minutes, and 0.958, respectively. The nighttime low glucose prediction model achieved an accuracy, sensitivity, specificity, and ROC AUC of: 86.5%, 55.3%, 91.6%, and 0.859, respectively. Conclusions: The consistency of the performance of the three predictive models when evaluated on different cohorts of subjects with T1D and T2D on different insulin therapies, including real-world data, offers reassurance for real-world efficacy.
Predicting Glucose Values: A New Era for Continuous Glucose Monitoring

Bernhard Kulzer,Lutz Heinemann

DOI: https://doi.org/10.1177/19322968241271925

Abstract:The last 25 years of CGM have been characterized above all by providing better and more accurate glucose values in real time and analyzing the measured glucose values. Trend arrows are the only way to look into the future, but they are often too imprecise for therapy adjustment. While AID systems provide algorithms to use glucose values for glucose control, this has not been possible with stand-alone CGM systems, which are most used by people with diabetes. By analyzing the measured values with algorithms, often supported by AI, this should be possible in the future. This provides the user with important information about the further course of the glucose level, such as during the night. Predictive approaches can be used by next-generation CGM systems. These systems can proactively prevent glucose events such as hypo- or hyperglycemia. With the Accu-Chek® SmartGuide Predict app, an integral part of a novel CGM system, and the Glucose Predict (GP) feature, people with diabetes have the first commercially available CGM system with predictive algorithms. It characterizes the CGM systems of the future, which not only analyze past values and current glucose values in the future, but also use these values to predict future glucose progression.
Concept and Implementation of a Novel Continuous Glucose Monitoring Solution With Glucose Predictions on Board

Timor Glatzer,Christian Ringemann,Daniel Militz,Wiebke Mueller-Hoffmann

DOI: https://doi.org/10.1177/19322968241269927

Abstract:The recently CE-marked continuous real-time glucose monitoring (rtCGM) solution Accu-Chek® (AC) SmartGuide Solution was developed to enable people with diabetes mellitus (DM) to proactively control their glucose levels using predictive technologies. The comprehensive solution consists of three components that harmonize well with each other. The CGM device is composed of a sensor applicator and a glucose sensor patch whose data are transferred to the connected smartphone by Bluetooth® Low Energy. The user interface of the CGM solution is powered by the AC SmartGuide app delivering current and past glucose metrics, and the AC SmartGuide Predict app providing a glucose prediction suite enabled by artificial intelligence (AI). This article describes the innovative CGM solution.
How to Use Continuous Glucose Monitoring Efficiently in Diabetes Management: Opinions and Recommendations by German Experts on the Status and Open Questions

Andreas Thomas,Thomas Haak,Astrid Tombek,Bernhard Kulzer,Dominic Ehrmann,Olga Kordonouri,Jens Kröger,Oliver Schubert-Olesen,Ralf Kolassa,Thorsten Siegmund,Nicola Haller,Lutz Heinemann

DOI: https://doi.org/10.1177/19322968241267768

2024-08-11

Abstract:Today, continuous glucose monitoring (CGM) is a standard diagnostic option for patients with diabetes, at least for those with type 1 diabetes and those with type 2 diabetes on insulin therapy, according to international guidelines. The switch from spot capillary blood glucose measurement to CGM was driven by the extensive and immediate support and facilitation of diabetes management CGM offers. In patients not using insulin, the benefits of CGM are not so well studied/obvious. In such patients, factors like well-being and biofeedback are driving CGM uptake and outcome. Apps can combine CGM data with data about physical activity and meal consumption for therapy adjustments. Personalized data management and coaching is also more feasible with CGM data. The same holds true for digitalization and telemedicine intervention ("virtual diabetes clinic"). Combining CGM data with Smart Pens ("patient decision support") helps to avoid missing insulin boluses or insulin miscalculation. Continuous glucose monitoring is a major pillar of all automated insulin delivery systems, which helps substantially to avoid acute complications and achieve more time in the glycemic target range. These options were discussed by a group of German experts to identify concrete gaps in the care structure, with a view to the necessary structural adjustments of the health care system.
Continuous Glucose Monitoring: Current Use in Diabetes Management and Possible Future Applications

Martina Vettoretti,Giacomo Cappon,Giada Acciaroli,Andrea Facchinetti,Giovanni Sparacino

DOI: https://doi.org/10.1177/1932296818774078

2018-05-22

Journal of Diabetes Science and Technology

Abstract:The recent announcement of the production of new low-cost continuous glucose monitoring (CGM) sensors, the approval of marketed CGM sensors for making treatment decisions, and new reimbursement criteria have the potential to revolutionize CGM use. After briefly summarizing current CGM applications, we discuss how, in our opinion, these changes are expected to extend CGM utilization beyond diabetes patients, for example, to subjects with prediabetes or even healthy individuals. We also elaborate on how the integration of CGM data with other relevant information, for example, health records and other medical device/wearable sensor data, will contribute to creating a digital data ecosystem that will improve our understanding of the etiology and complications of diabetes and will facilitate the development of data analytics for personalized diabetes management and prevention.

English Else
Continuous Glucose Monitoring in Healthy Adults—Possible Applications in Health Care, Wellness, and Sports

Roman Holzer,Wilhelm Bloch,Christian Brinkmann

DOI: https://doi.org/10.3390/s22052030

IF: 3.9

2022-03-05

Sensors

Abstract:Introduction: Continuous glucose monitoring (CGM) systems were primarily developed for patients with diabetes mellitus. However, these systems are increasingly being used by individuals who do not have diabetes mellitus. This mini review describes possible applications of CGM systems in healthy adults in health care, wellness, and sports. Results: CGM systems can be used for early detection of abnormal glucose regulation. Learning from CGM data how the intake of foods with different glycemic loads and physical activity affect glucose responses can be helpful in improving nutritional and/or physical activity behavior. Furthermore, states of stress that affect glucose dynamics could be made visible. Physical performance and/or regeneration can be improved as CGM systems can provide information on glucose values and dynamics that may help optimize nutritional strategies pre-, during, and post-exercise. Conclusions: CGM has a high potential for health benefits and self-optimization. More scientific studies are needed to improve the interpretation of CGM data. The interaction with other wearables and combined data collection and analysis in one single device would contribute to developing more precise recommendations for users.

engineering, electrical & electronic,chemistry, analytical,instruments & instrumentation
Continuous Glucose Monitoring Prediction

Julia Ann Jose,Trae Waggoner,Sudarsan Manikandan

DOI: https://doi.org/10.48550/arXiv.2101.02557

2021-01-05

Abstract:Diabetes is one of the deadliest diseases in the world and affects nearly 10 percent of the global adult population. Fortunately, powerful new technologies allow for a consistent and reliable treatment plan for people with diabetes. One major development is a system called continuous blood glucose monitoring (CGM). In this review, we look at three different continuous meal detection algorithms that were developed using given CGM data from patients with diabetes. From this analysis, an initial meal prediction algorithm was also developed utilizing these methods.

Other Quantitative Biology,Machine Learning
Demographic, Clinical, Psychosocial, and Behavioral Predictors of Continuous Glucose Monitor Use in Adults with Type 2 Diabetes

Emily L. Morrow,Andrew J. Spieker,Robert A. Greevy,McKenzie K. Roddy,Lindsay S. Mayberry

DOI: https://doi.org/10.1007/s11606-024-09101-1

IF: 5.7

2024-10-27

Journal of General Internal Medicine

Abstract:Continuous glucose monitor (CGM) use is increasing rapidly among people with type 2 diabetes, although little is known about predictors of CGM use beyond clinical and demographic information available in electronic medical records. Behavioral and psychosocial characteristics may also predict CGM use.

medicine, general & internal,health care sciences & services
Identifying the deficiencies of currently available CGM to improve uptake and benefit

Katharine D. Barnard‐Kelly,Maria Asunción Martínez‐Brocca,Timor Glatzer,Nick Oliver

DOI: https://doi.org/10.1111/dme.15338

IF: 3.5

2024-05-14

Diabetic Medicine

Abstract:Background and Aims The use of diabetes technologies is increasing worldwide, with health systems facilitating improved access to devices. Continuous glucose monitoring is a complex intervention that provides information on glucose concentration, rate and direction of change, historical data and alerts and alarms for extremes of glucose. These data do not themselves change glycaemia and require translation to a meaningful action for impact. It is, therefore, crucial that such systems advance to better meet the needs of individuals using them. Methods Narrative review of the use of, engagement with, limitations and unmet needs of continuous glucose monitoring systems. Results CGM devices have made a significant contribution to the self‐management of diabetes; however, challenges with access and user experience persist, with multiple limitations to uptake and benefit. These limitations include physical size and implementation, with associated stigma, alarm fatigue, sleep disturbance and the challenge of addressing large volumes of real‐time data. Greater personalisation throughout the continuous glucose monitoring journey, with a focus on usability, may improve the benefits derived from the device and reduce the burden of self‐management. Healthcare professionals may have unconscious biases that affect the provision of continuous glucose monitors due to deprivation, education, age, ethnicity and other characteristics. Conclusions Continuous glucose monitoring exerts a dose‐dependent response; the more it is used, the more effective it is. For optimal use, continuous glucose monitors must not just reduce the burden of management in one dimension but facilitate net improvement in all domains of self‐management for all users.

endocrinology & metabolism
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino,Thomas Danne,Richard M. Bergenstal,Stephanie A. Amiel,Roy Beck,Torben Biester,Emanuele Bosi,Bruce A. Buckingham,William T. Cefalu,Kelly L. Close,Claudio Cobelli,Eyal Dassau,J. Hans DeVries,Kim C. Donaghue,Klemen Dovc,Francis J. Doyle,Satish Garg,George Grunberger,Simon Heller,Lutz Heinemann,Irl B. Hirsch,Roman Hovorka,Weiping Jia,Olga Kordonouri,Boris Kovatchev,Aaron Kowalski,Lori Laffel,Brian Levine,Alexander Mayorov,Chantal Mathieu,Helen R. Murphy,Revital Nimri,Kirsten Nørgaard,Christopher G. Parkin,Eric Renard,David Rodbard,Banshi Saboo,Desmond Schatz,Keaton Stoner,Tatsuiko Urakami,Stuart A. Weinzimer,Moshe Phillip

DOI: https://doi.org/10.2337/dci19-0028

2019-06-08

Diabetes Care

Abstract:Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

endocrinology & metabolism
Monitoring Technologies – Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control

K. Dungan

2014-04-30

Abstract:It is recognized that traditional measures of glucose control (such as hemoglobin A1c [A1C]) provide little information regarding the need for day to day changes in therapies. While intermittent self-monitored blood glucose (SMBG) provides additional information with which to make treatment decisions, significant barriers to its use exist, such as inconvenience and lack of timely and regular feedback. Furthermore, important information regarding glucose trends may be missed. Continuous glucose monitoring (CGM) has become increasingly reliable and has demonstrated efficacy in terms of improving A1C, reducing hypoglycemia, and improving the time in target glucose range. Incremental progress continues to be made toward a fully functional artificial pancreas, of which CGM will play a vital role. As more and more data are presented to patients and providers, it has become increasingly paramount that the data are organized in a standardized way and that communication of data is streamlined using patients’ mobile devices where available and within the existing clinic infrastructure. Systems that provide immediate feedback to patients and decision support tools for patients and providers have demonstrated superior outcomes compared to routine SMBG alone. Alternate markers of glucose control may provide complementary information about glucose control and long-term prognosis. This chapter will review the latest evidence for use of professional and personal CGM, mobile glucose monitoring approaches, and biomarkers of glycemic control. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG .

Medicine
Does continuous glucose monitoring have clinical utility in contemporary management of diabetes?

FJ Cameron,GR Ambler

DOI: https://doi.org/10.1111/j.1440-1754.2004.00307.x

2004-03-01

Journal of Paediatrics and Child Health

Abstract:Continuous, automated and non-invasive blood glucose monitoring systems have long been a goal to assist management of diabetes mellitus. The first continuous, albeit invasive, device available in Australia is the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS), which is available for physician-supervised use to give a continuous blood glucose profile (5-minutely readings, viewable only after download by the physician) for periods of 72 h. With the availability of this technology, there is a need to assess the accuracy, reproducibility and ability to detect significant clinical events (particularly hypoglycaemia) and blood glucose patterns. The question of whether this technique allows long-term improvement of metabolic control also arises. We present four case studies to illustrate the use of CGMS in clinical practice and have reviewed the rapidly emerging literature. We conclude that CGMS is a useful clinical tool in the management of diabetes mellitus, provided that it is appropriately applied and the limitations are understood.

pediatrics
Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications

Giacomo Cappon,Martina Vettoretti,Giovanni Sparacino,Andrea Facchinetti

DOI: https://doi.org/10.4093/dmj.2019.0121

2019-01-01

Abstract:By providing blood glucose (BG) concentration measurements in an almost continuous-time fashion for several consecutive days, wearable minimally-invasive continuous glucose monitoring (CGM) sensors are revolutionizing diabetes management, and are becoming an increasingly adopted technology especially for diabetic individuals requiring insulin administrations. Indeed, by providing glucose real-time insights of BG dynamics and trend, and being equipped with visual and acoustic alarms for hypo- and hyperglycemia, CGM devices have been proved to improve safety and effectiveness of diabetes therapy, reduce hypoglycemia incidence and duration, and decrease glycemic variability. Furthermore, the real-time availability of BG values has been stimulating the realization of new tools to provide patients with decision support to improve insulin dosage tuning and infusion. The aim of this paper is to offer an overview of current literature and future possible developments regarding CGM technologies and applications. In particular, first, we outline the technological evolution of CGM devices through the last 20 years. Then, we discuss about the current use of CGM sensors from patients affected by diabetes, and, we report some works proving the beneficial impact provided by the adoption of CGM. Finally, we review some recent advanced applications for diabetes treatment based on CGM sensors.

endocrinology & metabolism
Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

D. Rodbard

DOI: https://doi.org/10.1089/dia.2017.0035

2017-06-01

Diabetes Technology & Therapeutics

Abstract:Continuous Glucose Monitoring (CGM) has been demonstrated to be clinically valuable, reducing risks of hypoglycemia and hyperglycemia, glycemic variability (GV), and improving patient quality of life for a wide range of patient populations and clinical indications. Use of CGM can help reduce HbA1c and mean glucose. One CGM device, with accuracy (%MARD) of approximately 10%, has recently been approved for self-adjustment of insulin dosages (nonadjuvant use) and approved for reimbursement for therapeutic use in the United States. CGM had previously been used off-label for that purpose. CGM has been demonstrated to be clinically useful in both type 1 and type 2 diabetes for patients receiving a wide variety of treatment regimens. CGM is beneficial for people using either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). CGM is used both in retrospective (professional, masked) and real-time (personal, unmasked) modes: both approaches can be beneficial. When CGM is used to suspend insulin infusion when hypoglycemia is detected until glucose returns to a safe level (low-glucose suspend), there are benefits beyond sensor-augmented pump (SAP), with greater reduction in the risk of hypoglycemia. Predictive low-glucose suspend provides greater benefits in this regard. Closed-loop control with insulin provides further improvement in quality of glycemic control. A hybrid closed-loop system has recently been approved by the U.S. FDA. Closed-loop control using both insulin and glucagon can reduce risk of hypoglycemia even more. CGM facilitates rigorous evaluation of new forms of therapy, characterizing pharmacodynamics, assessing frequency and severity of hypo- and hyperglycemia, and characterizing several aspects of GV.

Medicine
Prediction of Nocturnal Hypoglycemia in Adults with Type 1 Diabetes under Multiple Daily Injections Using Continuous Glucose Monitoring and Physical Activity Monitor

Arthur Bertachi,Clara Viñals,Lyvia Biagi,Ivan Contreras,Josep Vehí,Ignacio Conget,Marga Giménez

DOI: https://doi.org/10.3390/s20061705

IF: 3.9

2020-03-19

Sensors

Abstract:(1) Background: nocturnal hypoglycemia (NH) is one of the most challenging side effects of multiple doses of insulin (MDI) therapy in type 1 diabetes (T1D). This work aimed to investigate the feasibility of a machine-learning-based prediction model to anticipate NH in T1D patients on MDI. (2) Methods: ten T1D adults were studied during 12 weeks. Information regarding T1D management, continuous glucose monitoring (CGM), and from a physical activity tracker were obtained under free-living conditions at home. Supervised machine-learning algorithms were applied to the data, and prediction models were created to forecast the occurrence of NH. Individualized prediction models were generated using multilayer perceptron (MLP) and a support vector machine (SVM). (3) Results: population outcomes indicated that more than 70% of the NH may be avoided with the proposed methodology. The predictions performed by the SVM achieved the best population outcomes, with a sensitivity and specificity of 78.75% and 82.15%, respectively. (4) Conclusions: our study supports the feasibility of using ML techniques to address the prediction of nocturnal hypoglycemia in the daily life of patients with T1D on MDI, using CGM and a physical activity tracker.

engineering, electrical & electronic,chemistry, analytical,instruments & instrumentation
Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

David C Klonoff,Kevin T Nguyen,Nicole Y Xu,Alberto Gutierrez,Juan C Espinoza,Alaina P Vidmar,David C. Klonoff,Kevin T. Nguyen,Nicole Y. Xu,Juan C. Espinoza,Alaina P. Vidmar

DOI: https://doi.org/10.1177/19322968221110830

2022-07-22

Journal of Diabetes Science and Technology

Abstract:Journal of Diabetes Science and Technology, Ahead of Print. Background:Continuous glucose monitor (CGM) systems were originally intended only for people with diabetes. Recently, there has been interest in monitoring glucose concentrations in a variety of other situations. As data accumulate to support the use of CGM systems in additional states unrelated to diabetes, the use of CGM systems is likely to increase accordingly.Methods:PubMed and Google Scholar were searched for articles about the use of CGM in individuals without diabetes. Relevant articles that included sufficient details were queried to identify what cohorts of individuals were adopting CGM use and to define trends of use.Results:Four clinical user cases were identified: (1) metabolic diseases related to diabetes with a primary dysregulation of the insulin-glucose axis, (2) metabolic diseases without a primary pathophysiologic derangement of the insulin-glucose axis, (3) health and wellness, and (4) elite athletics. Seven trends in the use of CGM systems in people without diabetes were idenfitied which pertained to both FDA-cleared medical grade products as well as anticipated future products, which may be regulated differently based on intended populations and indications for use.Conclusions:Wearing a CGM has been used not only for diabetes, but with a goal of improving glucose patterns to avoid diabetes, improving mental or physical performance, and promoting motivate healthy behavioral changes. We expect that clinicians will become increasingly aware of (1) glycemic patterns from CGM tracings that predict an increased risk of diabetes, (2) specific metabolic glucotypes from CGM tracings that predict an increased risk of diabetes, and (3) new genetic and genomic biomarkers in the future.

English Else
Usefulness of functional outcome questionnaires in the primary screening of spinal disease

A. Mofidi,M. Sedhom,K. O'Shea,D. Moore,E. Fogarty,F. Dowling

DOI: https://doi.org/10.1007/BF03170101

2002-07-01

Journal of Spinal Disorders & Techniques

Abstract:
Leveraging continuous glucose monitoring as a catalyst for behaviour change: a scoping review

Michelle R Jospe,Kelli M Richardson,Ahlam A Saleh,Lauren C Bohlen,Jacob Crawshaw,Yue Liao,Kristin Konnyu,Susan M Schembre

DOI: https://doi.org/10.1186/s12966-024-01622-6

2024-07-10

Abstract:Background: Amidst the escalating prevalence of glucose-related chronic diseases, the advancements, potential uses, and growing accessibility of continuous glucose monitors (CGM) have piqued the interest of healthcare providers, consumers, and health behaviour researchers. Yet, there is a paucity of literature characterising the use of CGM in behavioural intervention research. This scoping review aims to describe targeted populations, health behaviours, health-related outcomes, and CGM protocols in randomised controlled trials (RCTs) that employed CGM to support health behaviour change. Methods: We searched Ovid MEDLINE, Elsevier Embase, Cochrane Central Register of Controlled Trials, EBSCOhost PsycINFO, and ProQuest Dissertations & Theses Global from inception to January 2024 for RCTs of behavioural interventions conducted in adults that incorporated CGM-based biological feedback. Citation searching was also performed. The review protocol was registered ( https://doi.org/10.17605/OSF.IO/SJREA ). Findings: Collectively, 5389 citations were obtained from databases and citation searching, 3995 articles were screened, and 31 were deemed eligible and included in the review. Most studies (n = 20/31, 65%) included adults with type 2 diabetes and reported HbA1c as an outcome (n = 29/31, 94%). CGM was most commonly used in interventions to target changes in diet (n = 27/31, 87%) and/or physical activity (n = 16/31, 52%). 42% (n = 13/31) of studies provided prospective CGM-based guidance on diet or activity, while 61% (n = 19/31) included retrospective CGM-based guidance. CGM data was typically unblinded (n = 24/31, 77%) and CGM-based biological feedback was most often provided through the CGM and two-way communication (n = 12/31, 39%). Communication typically occurred in-person (n = 13/31, 42%) once per CGM wear (n = 13/31; 42%). Conclusions: This scoping review reveals a predominant focus on diabetes in CGM-based interventions, pointing out a research gap in its wider application for behaviour change. Future research should expand the evidence base to support the use of CGM as a behaviour change tool and establish best practices for its implementation. Trial registration: doi.org/10.17605/OSF.IO/SJREA.
Machine Learning based prediction of Glucose Levels in Type 1 Diabetes Patients with the use of Continuous Glucose Monitoring Data

Jakub J. Dylag

DOI: https://doi.org/10.48550/arXiv.2302.12856

2023-02-25

Abstract:A task of vital clinical importance, within Diabetes management, is the prevention of hypo/hyperglycemic events. Increasingly adopted Continuous Glucose Monitoring (CGM) devices offer detailed, non-intrusive and real time insights into a patient's blood glucose concentrations. Leveraging advanced Machine Learning (ML) Models as methods of prediction of future glucose levels, gives rise to substantial quality of life improvements, as well as providing a vital tool for monitoring diabetes. A regression based prediction approach is implemented recursively, with a series of Machine Learning Models: Linear Regression, Hidden Markov Model, Long-Short Term Memory Network. By exploiting a patient's past 11 hours of blood glucose (BG) concentration measurements, a prediction of the 60 minutes is made. Results will be assessed using performance metrics including: Root Mean Squared Error (RMSE), normalised energy of the second-order differences (ESOD) and F1 score. Research of past and current approaches, as well as available dataset, led to the establishment of an optimal training methodology for the CITY dataset, which may be leveraged by future model development. Performance was aligned with similar state-of-art ML models, with LSTM having RMSE of 28.55, however no significant advantage was observed over classical Auto-regressive AR models. Compelling insights into LSTM prediction behaviour could increase public and legislative trust and understanding, progressing the certification of ML models in Artificial Pancreas Systems (APS).

Machine Learning,Artificial Intelligence
Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications

Agata Chobot,Claudia Piona,Bruno Bombaci,Olga Kamińska-Jackowiak,Valentina Mancioppi,Stefano Passanisi

DOI: https://doi.org/10.3390/children11080907

2024-07-27

Abstract:Continuous glucose monitoring (CGM) systems, including real-time CGM and intermittently scanned CGM, have revolutionized diabetes management, particularly in children and adolescents with type 1 diabetes (T1D). These systems provide detailed insights into glucose variability and detect asymptomatic and nocturnal hypoglycemia, addressing limitations of traditional self-monitoring blood glucose methods. CGM devices measure interstitial glucose concentrations constantly, enabling proactive therapeutic decisions and optimization of glycemic control through stored data analysis. CGM metrics such as time in range, time below range, and coefficient of variation are crucial for managing T1D, with emerging metrics like time in tight range and glycemia risk index showing potential for enhanced glycemic assessment. Recent advancements suggest the utility of CGM systems in monitoring the early stages of T1D and individuals with obesity complicated by pre-diabetes, highlighting its therapeutic versatility. This review discusses the current CGM systems for T1D during the pediatric age, established and emerging metrics, and future applications, emphasizing the critical role of CGM devices in improving glycemic control and clinical outcomes in children and adolescents with diabetes.

[A case of auditory agnosia].

Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App

Predicting Glucose Values: A New Era for Continuous Glucose Monitoring

Concept and Implementation of a Novel Continuous Glucose Monitoring Solution With Glucose Predictions on Board

How to Use Continuous Glucose Monitoring Efficiently in Diabetes Management: Opinions and Recommendations by German Experts on the Status and Open Questions

Continuous Glucose Monitoring: Current Use in Diabetes Management and Possible Future Applications

Continuous Glucose Monitoring in Healthy Adults—Possible Applications in Health Care, Wellness, and Sports

Continuous Glucose Monitoring Prediction

Demographic, Clinical, Psychosocial, and Behavioral Predictors of Continuous Glucose Monitor Use in Adults with Type 2 Diabetes

Identifying the deficiencies of currently available CGM to improve uptake and benefit

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Monitoring Technologies – Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control

Does continuous glucose monitoring have clinical utility in contemporary management of diabetes?

Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications

Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Prediction of Nocturnal Hypoglycemia in Adults with Type 1 Diabetes under Multiple Daily Injections Using Continuous Glucose Monitoring and Physical Activity Monitor

Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?

Usefulness of functional outcome questionnaires in the primary screening of spinal disease

Leveraging continuous glucose monitoring as a catalyst for behaviour change: a scoping review

Machine Learning based prediction of Glucose Levels in Type 1 Diabetes Patients with the use of Continuous Glucose Monitoring Data

Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications